CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05886634
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:01.790697+00:00
Published At: 2025-10-20T00:00:00+00:00
Record Updated At: 2025-10-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Dedifferentiated Liposarcoma", "Soft Tissue Sarcoma", "Sarcoma,Soft Tissue", "Sarcoma", "Recurrent Dedifferentiated Liposarcoma", "Unresectable Dedifferentiated Liposarcoma", "Metastatic Dedifferentiated Liposarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-20"
protocolSection.identificationModule.nctId: "NCT05886634"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.